(BWAY) BrainsWay Ltd. PESTLE Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BWAY) BrainsWay Ltd. Complete Analysis Pack
Your Shortcut to Market Insight Starts Here
This BrainsWay Ltd. PESTLE Analysis shows how political, economic, social, technological, legal, and environmental forces affect the company and why it matters for strategy or investment; the page includes a real preview of the report so you can judge style and depth, and purchasing the full version delivers the complete, ready-to-use company-specific analysis.
Political factors
Israel-headquartered, global market exposure
BrainsWay Ltd., headquartered in Jerusalem, sells in the United States, Europe, Israel, and other markets, so it faces policy risk in at least 4 regions at once. Cross-border rules on imports, medical devices, and reimbursement can slow hospital adoption, while mental health funding directly affects demand. Israel’s geopolitical risk can also disrupt logistics and weigh on investor sentiment.
Public funding for mental health treatment
BrainsWay sells to hospitals and medical centers that often depend on government healthcare budgets, so public mental health funding directly shapes demand. The WHO says governments still spend about 2% of health budgets on mental health, with high-income countries averaging about $65 per person, so funding gaps can slow installations and patient access. Policy that favors outpatient care and early intervention can speed adoption of non-invasive treatments like BrainsWay's devices.
Regulatory oversight in major markets
BrainsWay Ltd. sells into tightly regulated healthcare markets in the United States and Europe, where clearance, reimbursement, and post-market monitoring can slow new indication launches. In 2024, revenue was $44.6 million, so even small delays in FDA and EU review can matter. Political focus on patient safety and health technology assessment also shapes payer coverage, while stable rules support long Deep TMS product cycles.
Healthcare procurement by public institutions
Healthcare procurement by public institutions can slow BrainsWay Ltd. sales because hospitals and psychiatric centers often buy through centralized, budget-led processes. That means one tender can cover many sites, but delayed capital approvals can also push revenue conversion by one or more quarters.
- Central buying creates long sales cycles.
- Public tenders can open multi-site access.
- Budget delays can defer revenue recognition.
International trade and market access policy
BrainsWay sells across borders, so tariffs, customs checks, and medical device import rules can directly affect delivery time and compliance cost. Trade friction between regions can slow distributor onboarding and make hospital access harder in smaller overseas markets. Stable trade ties help BrainsWay add new hospital systems and expand channel coverage faster.
- Tariffs and customs raise landed cost.
- Import rules can delay shipments.
- Stable policy supports new distributors.
Policy Risk and Mental Health Funding Could Shape BrainsWay’s Sales
BrainsWay Ltd. faces political risk in the U.S., Europe, Israel, and other markets, so FDA, EU, and import rules can delay device launches and shipments. Public mental health budgets matter too: WHO says governments spend about 2% of health budgets on mental health, with high-income countries near $65 per person.
| Factor | Latest data | Why it matters |
|---|---|---|
| Revenue | $44.6M, 2024 | Policy delays can hit sales |
| Mental health spend | ~2% of health budgets | Funding shapes demand |
What is included in the product
Detailed Word Document
Examines how Political, Economic, Social, Technological, Environmental, and Legal forces shape BrainsWay Ltd.’s opportunities and risks.
Customizable Excel Spreadsheet
A concise BrainsWay Ltd. PESTLE snapshot that simplifies external risk review and speeds up strategy discussions.
Reference Sources
Cites primary industry reports, clinical trial registries, regulatory filings, and financial statements to speed due diligence and let investors verify BrainsWay claims quickly.
Economic factors
Capital spending by hospitals
BrainsWay Ltd. sells clinic equipment, so hospital capital budgets directly shape demand. In 2025, U.S. policy rates stayed at 4.25%-4.50%, and tighter credit made it harder for clinics to fund new devices. When budgets improve, hospitals are more willing to add treatment systems, but slower economies can push sales cycles out by months.
Reimbursement-driven demand
BrainsWay Ltd.'s demand is reimbursement-led: a typical TMS course can take 20-30 sessions, so payer coverage directly shapes patient volume and clinic use. Better insurance terms lower out-of-pocket cost and lift adoption, while weak or unclear coverage can delay starts even when clinical need is high. Revenue growth still hinges on payer acceptance in core U.S. and ex-U.S. markets.
Global healthcare spending growth
Global health spending keeps lifting demand for BrainsWay Ltd.'s therapies: U.S. national health spending is projected to rise 7.5% in 2025 to $6.8 trillion, while WHO says people aged 60+ will reach 1.4 billion by 2030. More budget means more room for depression, OCD, smoking cessation, and other neurostimulation use. In tighter spending cycles, device buys and clinic growth can slow.
Currency exposure across regions
BrainsWay Ltd. sells across the U.S., Europe, and Israel, so revenue lands in USD, EUR, and ILS. A stronger U.S. dollar can cut the translated value of overseas sales, while FX swings can also move margins and operating costs. That makes distributor pricing and 2025–2026 forecast plans harder to lock in.
- 3 core currencies: USD, EUR, ILS
- FX swings hit revenue and margins
- USD strength can lower translated sales
- Pricing and forecasts need constant resets
Cost of clinical adoption
BrainsWay Ltd.'s non-invasive neurostimulation faces upfront clinic costs: device purchase, staff training, and workflow changes. A standard acute course can run 20-30 sessions, so providers compare that setup cost with lower-cost drug therapy and other options. Adoption improves when the device lifts throughput and cuts longer-term care spend.
- Upfront device and setup costs matter most
- 20-30 sessions shape clinic economics
- Clear ROI supports psychiatric and hospital use
BrainsWay Faces Rate, Reimbursement, and FX Headwinds
BrainsWay Ltd. depends on clinic budgets, payer coverage, and FX. In 2025, U.S. rates stayed 4.25%-4.50%, which kept financing tight for device buys. U.S. health spending is projected to reach $6.8 trillion in 2025, but slower reimbursement or a strong USD can still delay orders and cut translated sales.
| Factor | 2025/2026 data |
|---|---|
| Rates | 4.25%-4.50% |
| U.S. health spend | $6.8T in 2025 |
| FX risk | USD, EUR, ILS exposure |
Same Document Delivered
BrainsWay Ltd. PESTLE Analysis
The preview shown here is the exact BrainsWay Ltd. PESTLE analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.
Sociological factors
Rising mental health awareness
Rising mental health awareness supports demand for depression and anxiety care, and the World Health Organization says 1 in 8 people live with a mental disorder. Patients are more willing to seek care now, so non-drug therapies like BrainsWay Ltd.'s treatments can reach a wider market.
Awareness campaigns also reduce stigma, which can lift diagnosis and referral rates. That matters because depression is a leading cause of disability worldwide, and more treatment-seeking can turn unmet need into paid demand.
Preference for non-invasive treatment
BrainsWay Ltd.’s non-invasive Deep TMS fits patient demand to avoid surgery and the side effects of systemic drugs, which helps in treatment-resistant depression and OCD cases. Office-based sessions also suit patients who want outpatient care, and that ease can lift adoption by psychiatrists and hospital centers. This matters in a large market: depression affects about 280 million people worldwide, and roughly 30% do not respond well to first-line treatment.
High burden of chronic psychiatric illness
BrainsWay Ltd. benefits from the high burden of chronic psychiatric illness: WHO says about 1 in 8 people worldwide lives with a mental disorder, and depression affects roughly 280 million people. Major depressive disorder, OCD, PTSD, and addiction often need repeated care, so symptom persistence keeps demand high for non-drug therapies like deep TMS and accessible, evidence-based treatment.
Ageing and neurodegenerative demand
Ageing lifts demand for BrainsWay Ltd. beyond psychiatry: WHO estimates about 55 million people live with dementia worldwide, Parkinson’s affects over 10 million, and MS and stroke survivors also need long rehab support. As the global 65+ population keeps rising, these disorders become more common, so BrainsWay’s non-invasive therapy stays relevant for function and quality of life.
That broadens BrainsWay Ltd.’s clinical base and supports use in Alzheimer’s disease, MS, post-stroke rehab, and Parkinson’s care. The message is simple: more older patients means a bigger need for therapies that help people keep moving, thinking, and living independently.
- 55 million dementia cases worldwide
- 10+ million Parkinson’s cases worldwide
- Ageing expands neurological demand
- Quality-of-life care supports adoption
Smoking cessation and lifestyle-related care
Smoking cessation is a large behavior-health need: WHO says tobacco still causes over 8 million deaths a year, and U.S. adult smoking was 11.6% in 2022, keeping demand for non-drug support high. For BrainsWay Ltd., this fits prevention-led care and can widen use of clinic-based, lifestyle-focused treatment.
As more patients and providers seek non-pharmacological help, broader wellness pathways can lift treatment volumes beyond depression and OCD. This can support repeat visits, referrals, and payer interest in lower-risk care.
- High unmet need keeps demand durable
- Non-drug care fits prevention trends
- More wellness use can raise volumes
Rising Mental Health Needs Fuel Demand for BrainsWay’s Noninvasive Deep TMS
Rising mental health awareness and lower stigma support BrainsWay Ltd.'s demand, with WHO saying 1 in 8 people live with a mental disorder and depression affecting about 280 million. Patients also want non-drug, non-invasive care, so Deep TMS fits outpatient use and treatment-resistant cases. Ageing and chronic illness keep the need high in neurology too.
| Driver | Data |
|---|---|
| Mental disorders | 1 in 8 people |
| Depression | 280 million |
| Tobacco deaths | 8M+ yearly |
Technological factors
Patented Deep TMS platform
BrainsWay Ltd.’s Deep TMS platform uses an H-coil design to reach deeper and broader brain regions than standard coils, which is its main edge in non-invasive brain stimulation. The same device family supports multiple cleared indications, so one platform can serve more than one market without a full product reset. That technology-led model is central to BrainsWay Ltd.’s commercial pitch and helps support higher-value clinical adoption.
Multi-indication clinical expansion
BrainsWay Ltd.’s Deep TMS platform spans psychiatric and neurological uses, so one system can support multiple care paths. Each new clearance or positive study boosts the value of its installed base and widens commercial optionality. That matters because clinical versatility is a key medtech edge: more evidence can mean more sites, more patients, and longer device use.
Clinic-based device workflow
BrainsWay’s clinic workflow hinges on trained operators, clear treatment protocols, and high device uptime; a stalled system can cut same-day capacity and hurt clinic economics. Simple setup and reliable hardware help adoption, while software updates and session tracking support standardized care across its FDA-cleared deep TMS platform.
Strong technical support also matters for retention, because clinics need fast fixes to keep sessions on schedule and patients on plan.
Research and trial dependence
BrainsWay Ltd.’s growth still depends on research and trial data because neurostimulation buyers want proof, not just clearance. Strong peer-reviewed results and real-world outcomes help win physician trust and payer coverage, while weak evidence can slow uptake even when the device is on the market.
This matters in new markets, where validation often decides whether a clinic adopts the system. In this field, the trial record is part of the product.
- More data speeds adoption.
- Peer review builds confidence.
- Payer access needs proof.
- Weak evidence slows sales.
Digital integration potential
Modern neuropsychiatry is moving toward digital screening, remote symptom tracking, and outcomes tracking, so BrainsWay Ltd. can gain from tighter links to electronic medical records and clinic software. Better data capture makes each treatment easier to track, compare, and report, which also helps clinics prove value to payers and patients.
- Faster patient onboarding
- Cleaner outcome reporting
- Stronger follow-up after treatment
- Better sales proof for clinics
Stronger digital connectivity can also lift post-treatment follow-up and support repeat use, since clinic teams can see response data faster and act sooner.
BrainsWay’s Deep TMS Edge Hinges on Uptime and Data
BrainsWay Ltd.’s tech edge is Deep TMS: an H-coil design that reaches broader brain regions and supports multiple cleared uses on one platform. That helps clinic throughput, but growth still depends on strong trial data, fast software updates, and reliable uptime so sites can track outcomes and keep sessions on schedule.
| Factor | 2025/2026 signal |
|---|---|
| Core tech | Deep TMS H-coil platform |
| Commercial value | One device, multiple indications |
| Operational need | High uptime, fast support |
| Data need | Outcome tracking |
Legal factors
Medical device regulatory clearance
BrainsWay Ltd. must keep device clearances in the U.S., Europe, Israel, and other markets, because each approval sets the exact indications it can sell. FDA and CE changes can narrow or expand claims, and even a labeling shift can change revenue upside by limiting who can be treated. Ongoing quality and post-market compliance are not optional; a lapse can pause commercialization and delay new launches.
Clinical evidence and claims control
BrainsWay Ltd. must keep every marketing claim tied to clinical data, especially across depression, OCD, addiction, and neurological uses. Regulators can challenge unsupported efficacy language, so strong trial files and clean endpoint records are a legal shield. Across these 4 main indication buckets, precise evidence control lowers the risk of label, ad, or disclosure disputes.
Data privacy and patient records
BrainsWay Ltd. handles protected health information in clinics, so HIPAA in the U.S. and GDPR in Europe drive strict controls for software, follow-up data, and patient records. HIPAA civil penalties can reach $2.1 million per year for repeated violations, while GDPR fines can hit €20 million or 4% of global annual turnover. Any breach can trigger claims, lost trust, and lower clinic adoption.
Intellectual property protection
BrainsWay’s differentiated neurostimulation platform relies on patents and proprietary know-how, so IP protection is central to defending pricing and share. Patent disputes can hit valuation fast; for example, BrainsWay reported FY2025 revenue of about $46 million, so even small IP shocks can matter. Strong IP also helps support licensing deals and global rollout in regulated markets.
- Patents protect the core platform
- Disputes can pressure valuation
- IP supports licensing and expansion
Product liability and safety obligations
BrainsWay Ltd. faces strict product liability risk because its non-invasive brain stimulation devices must meet safety, labeling, and adverse-event reporting duties. Hospitals and medical centers expect clear use instructions and risk controls, and missed protocol steps can turn a clinical issue into legal exposure.
Safety compliance supports long-term sales.
Protocol drift raises liability risk fast.
Clear labeling helps hospital adoption.
BrainsWay’s Legal Risks Could Quickly Dent a $46M Revenue Base
BrainsWay Ltd.’s legal risk is tied to device clearances, claims, and data rules; any FDA, CE, HIPAA, or GDPR lapse can slow sales or trigger fines. FY2025 revenue was about $46 million, so even a small legal hit can matter. Patent protection also matters because it supports pricing and global rollout.
| Legal factor | Latest data |
|---|---|
| FY2025 revenue | About $46 million |
| HIPAA penalty | Up to $2.1 million per year |
| GDPR fine | €20 million or 4% of turnover |
Environmental factors
Low chemical waste treatment model
BrainsWay’s device-based therapy avoids on-site drug manufacturing, so it can cut chemical waste versus medication-heavy care paths. The model still uses power and equipment, but the footprint is relatively clean, with 0 routine drug compounding at the clinic level. That can appeal to sustainability-focused healthcare buyers in 2025–2026.
Electric power usage in clinics
BrainsWay Ltd.’s dTMS systems need steady electricity and a controlled room, so power outages can stop care fast. U.S. hospitals spent about $10.8 billion on electricity in 2024, making energy efficiency a real cost issue. Clinics also face tougher emissions targets, with many health systems aiming for net-zero by 2050, so low-energy equipment can help procurement.
Electronic equipment lifecycle
BrainsWay’s hardware creates lifecycle duties for devices, parts, and spares, so design for repair and longer component life matters. The world generated 62 million tonnes of e-waste in 2022, but only 22.3% was formally recycled, which raises end-of-life pressure on manufacturers and distributors. Responsible take-back and recycling can cut disposal risk and lower the environmental footprint of replacement cycles.
Global shipping footprint
BrainsWay Ltd. ships internationally, so freight and packaging add direct emissions and can raise exposure to delays, damage, and border disruption. Maritime shipping alone is about 3% of global CO2 emissions, so long lanes can matter fast.
Regional inventory planning can cut freight intensity by shortening routes and lowering air-freight use, which also reduces packaging waste. Customers and hospital buyers are increasingly asking for lower-impact logistics, so transport choices now affect both cost and brand risk.
- Global distribution lifts transport emissions.
- Long routes increase supply-chain risk.
- Regional stock can reduce freight intensity.
- Lower-impact logistics are a buyer priority.
Healthcare sustainability pressure
Hospitals and medical centers are under growing pressure to report environmental performance, and healthcare is estimated to drive about 4.4% of global net emissions. That pushes procurement teams to favor efficient devices with lower waste, so sustainability can now affect tender scores in Europe and other regulated markets.
- 4.4% of global emissions
- Lower waste can win tenders
- EU buyers face ESG reporting pressure
BrainsWay’s Green Edge Still Hinges on E-Waste and Power Use
BrainsWay Ltd. has a lighter waste profile than drug-based care, but it still faces power use, transport emissions, and device end-of-life duties. Healthcare drives about 4.4% of global net emissions, and only 22.3% of 62 million tonnes of e-waste was formally recycled in 2022, so repair, take-back, and regional stock matter.
| Factor | Data |
|---|---|
| Healthcare emissions | 4.4% |
| E-waste recycled | 22.3% |
| Global e-waste | 62m tonnes |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.